Drugs / TQB2101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07113925 | Aug → Dec 2025 overdue | hematopoietic and lymphoid cell neoplasm | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06948539 | Apr 2025 → Oct 2026 expected | breast cancer, colorectal cancer, lung cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗
2025年，中国生物制药共有3款ADC药物（包括1款双抗ADC）首次获批临床，构建了覆盖不同靶点的ADC创新矩阵。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06948539 ↗ |
| Known as | TQB2101 for Injection | “TQB2101 for Injection is an ROR1 ADC, an antibody-drug conjugate.” NCT07113925 ↗ |
| Modality | Other / unclassified | “TQB2101 for injection is a receptor tyrosine kinase-like orphan receptor-1 antibody drug conjugate.” NCT06948539 ↗ |
| Route | Intravenous | “Intravenous injection” NCT07113925 ↗ |
| Target | ROR1 | “targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).” NCT07113925 ↗ |